Androgen dependency of hepatocarcinogenesis in TGFα transgenic mice

Liver

Volumn 20, Issue 3, 2000, Pages 228-233

  Matsumoto, Tatsuhiko ^a   Takagi, Hitoshi ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; LH RH agonist; Sex difference; TGF ; Transgenic mice

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CYCLINE; LEUPRORELIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER SUSCEPTIBILITY; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER WEIGHT; MALE; NONHUMAN; NORTHERN BLOTTING; RAT; SEX DIFFERENCE; TRANSGENIC MOUSE;

ANIMALS; BLOTTING, NORTHERN; BODY WEIGHT; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; DIHYDROTESTOSTERONE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HORMONE REPLACEMENT THERAPY; LEUPROLIDE; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; ORCHIECTOMY; ORGAN SIZE; PROLIFERATING CELL NUCLEAR ANTIGEN; RNA, MESSENGER; SEX CHARACTERISTICS; TESTOSTERONE; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0034116411     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2000.020003228.x     Document Type: Article

References (29)

1. HIGGINSON J. The epidemiology of primary carcinoma of the liver. In: Pack GT, Islami AH, eds. Tumors of the liver. Berlin and New York: Springer-Verlag, 1970: 38-52.
2. BIANCIFIORI C J. Hepatomas in CBA/cb/Se mice and liver lesions in golden hamsters induced by hydrazine sulfate. J Natl Cancer Inst 1970; 44: 943-5.
3. TOH Y D. Physiological and biochemical review of sex differences and carcinogenesis with particular references to the liver. Adv Cancer Res 1973; 18: 155-209.
4. VESSELINOVITCH S D, ITZE L, MIHAILOVICH N, et al. Modifying role of partial hepatectomy and gonadectomy in ethyl-nitrosourea-induced hepatocarcinogenesis. Cancer Res 1980; 40: 1538-42.
5. BLANK A, ASTROM A, HASSON T, et al. Pituitary grafts modify sex differences in liver tumor formation in the rat following initiation with diethylnitrosamine and different promotion regimens. Carcinogenesis 1986; 7: 981-5.
6. LIVER CANCER STUDY GROUP OF JAPAN. Survey and follow-up study of primary liver cancer in Japan. Report 12. Acta Hepatol Jpn 1997: 38; 317-30.
7. NG I O, NG M M, LAI E C, FAN S T. Better survival in female patients with hepatocellular carcinoma. Cancer 1995; 75: 18-22
8. TARAO K, SHIMIZU A, HARADA M, et al. Evidence of sex difference in DNA synthesis in hepatocellular carcinoma. Jpn J Cancer Res 1991; 82: 922-6.
9. YU L, NAGASUE N, MAKINO Y, NAKAMURA T. Effect of androgen and their manipulation on cell growth and androgen receptor (AR) levels in AR-positive and negative human hepatocellular carcinoma. J Hepatol 1995; 22: 295-302.
10. NAGASUE N, CHANG Y C, HAYASHI T, et al. Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection. Ann Surg 1989; 209: 424-7.
11. D'ARVILLE C N, JOHNSON P J. Growth factors, endocrine aspects and hormonal treatment in hepatocellular carcinoma-an overview. J Steroid Biochem Mol Biol 1990: 37; 1007-12.
12. JHAPPAN C, STAHLE C, HARKINS R N, et al. TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990; 61: 1137-46.
13. TAKAGI H, SHARP R, HAMMERMEISTER C, et al. Molecular and genetic analysis of liver oncogenesis in TGFα transgenic mice. Cancer Res 1992; 52: 5171-7.
14. SALOMON D S, KIM N, SAEKI T, CIARDIELLO F. Transforming growth factor-alpha: an oncodevelopmental growth factor. Cancer Cells 1990: 2; 389-97.
15. GUSTAFFSON J A, MODE A, NORSTEDT G, et al. Growth hormone: a regulator of the sexually differentiated steroid metabolism in rat liver. Developmental Pharmacology. New York: Allan R Liss Inc, 1983: 37-59.
16. WARD J. Morphology of potential preneoplastic lesions and liver tumors in mice and a comparison with other species. In: Popp J, ed. Mouse liver neoplasia: current perspective. Washington DC: Hemisphere Publishing Corp, 1984: 1-26.
17. TAKAGI H, SHARP R, TAKAYAMA H, ANVER M R, WARD J M, MERLINO G. Collaboration between growth factors and diverse chemical carcinogens in hepatocarcinogenesis of transforming growth factor a transgenic mice. Cancer Res 1993; 53: 4329-36.
18. LEE G H, MERLINO G, FAUSTO N. Development of liver tumors in transforming growth factor α transgenic mice. Cancer Res 1992: 52; 5162-70.
19. KIRA S, NAKANISHI T, SUEMORI S, KITAMOTO M, WATANABE Y, KAJIYAMA G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 1997; 17: 177-82.
20. COLLIER J D, GUO K, GULLICK W J, BASSENDINE M F, BURT A D. Expression of transforming growth factor alpha in human hepatocellular carcinoma. Liver 1993; 113: 151-5.
21. MORIMITSU Y, HSIA C C, KOJIRO M, TABOR E. Nodules of less differential tumor within or adjacent hepatocellular carcinoma: relative expression of transforming growth factor-α and its receptor in the different areas of tumor. Hum Pathol 1995; 26: 1126-32.
22. DONATO F, TAGGER A, CHIESA R, et al. Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology 1997; 26: 579-84.
23. HSIA C C, AXIOTIS C A, DI BESGLIE A M, TABOR E. Transforming growth factor alpha in human hepatocellular carcinoma and coexpression with hepatitis B surface antigen in adjacent liver. Cancer 1991; 70: 1049-56.
24. MATSUURA B, TANIGUCHI Y , OHTA Y. Efficacy of antiandrogen treatment on chemical hepatocarcinogenesis in rats. J Hepatol 1994; 21: 187-93.
25. GRIMALDI C, BLEIBERG H, GAY F, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for research and treatment of cancer multicentric double-blind trial. J Clin Oncol 1998; 16:411-7.
26. MARTINEZ-CEREZO F J, TOMAS A, DONOSO L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994; 20: 702-6.
27. CASTELLS A, BRUIX J, BRU C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double- blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917-22.
28. ENGSROM P F, LEVIN B, MOERTEL C G, SCHUTT A. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 1990; 65: 2641-3.
29. CLIP GROUP (CANCER OF THE LIVER ITALIAN PROGRAMME). Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial. Lancet 1998; 352: 17-20.